A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765 (AZD6765 EEG)
This study has been terminated.
( The benefit of halting the study to analyze the available data outweighs the benefit of delaying the analysis to include data from remaining treatment periods )
Study NCT01130909
Information provided by AstraZeneca
First Received on May 19, 2010.
Last Updated on December 14, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
